ArticleProbiotics and antimicrobial proteins2026
The Adaptive Laboratory Evolution Technology Enhances Sulforaphane Production of Lactobacillus plantarum CR12.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
T he sulforaphane production of wild-type Lactobacillus plantarum CR12 (L. plantarum CR12) is limited. Researchers found that adaptive laboratory evolution (ALE) technology can enhance the production of microorganism by altering the growth environment of microorganisms. However, the effectiveness of enhancing the transformation function of L. plantarum CR12 and the safety of the adaptive strain are unknown. To clarify the above problem, ALE technology was used to enhance the sulforaphane conversion rate of L. plantarum CR12. The results showed that the glucoraphanin conversion rate, sulforaphane production rate, and sulforaphane conversion efficiency of adaptive strain were significantly higher than those of the wild-type strain. The adaptive strain could produce sulforaphane in vivo and regulate the gut microbiota structure. The genomes showed that the adaptive strain consists of a 4,165,885 bp chromosome with a GC content of 36.8%, encoding 4172 protein-coding genes. Compared with the wild-type strain, the adaptive strain expresses more glycoside hydrolases and glycosyl transferases, indicating that the adaptive strain possesses higher carbohydrate metabolic capability. Genes related to glucoraphanin metabolism (cliT, bglF, and bglA) were detected in both the genomes of the wild-type strain and adaptive strain, indicating that both the wild-type strain and adaptive strain possess sulforaphane production capabilities. Therefore, the adaptive strain can be safely used to increase the in vivo production of sulforaphane, ultimately improving human health. This research is aimed at providing genetic evidence for further formulating rational genetic engineering strategies to transform the wild-type strain into an overproducer.
Indexed as
Identifiers
41026407What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.